Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.

Squamous Cell Carcinoma of the Head and Neck Clinical Trial

— OPHELIA  

Official title:

Phase II(Window) Preoperative Study of Olaparib With Cisplatin or With Durvalumab (MEDI4736) or Alone or no Treatment in Patients With Histologically Proven Squamous Cell Carcinoma of the Head and Neck Who Are Candidates for Surgery.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02882308
• Other study ID #: HE5A/15
• Secondary ID: 2015-005268-41
• Status: Completed
• Phase: Phase 2
• Start date: October 20, 2016
• Est. completion date: January 10, 2020

Study information

• Verified date: February 2020
• Source: Hellenic Cooperative Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

OPHELIA (OPHELIA (OlaParib and durvalumab in HEad and neck squamous celL carcInomA) trial is a Greek, investigator-initiated, randomized open-label window-of-opportunity phase II study. Patients with operable histologically documented squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx will be randomized between combination with durvalumab and olaparib, cisplatin and olaparib, monotherapy with olaparib or no treatment, before starting standard treatment.

Description:

OPHELIA is a window-of-opportunity phase II study randomized between combination with durvalumab and olaparib, cisplatin and olaparib, monotherapy with olaparib or no treatment, before starting standard treatment.

Although patients will be randomized between the 4 arms, no formal comparison between the 4 arms will be performed.Patients allocated to the olaparib monotherapy arm will serve as a proof-of-concept to interpret the mechanism of action of olaparib. Patients allocated in the "no treatment" group will be used as control.

The primary endpoint will be the change in the tumour Ki-67 before and after treatment with the combination of olaparib + durvalumab or olaparib + cisplatin or olaparib monotherapy. Secondary endpoints will be early tumour response by RECIST criteria, pathologic complete response rate, tolerability to treatment and surgical complications rate, and optionally, metabolic response assessed by FDG-PET/CT scan. Translational correlates will be tested in tumour tissue, plasma and germline DNA.

All the endpoints will be analyzed by an "as treated analysis" since the trial does not include a formal comparison of the treatment arms.

Administration of olaparib monotherapy has been associated with reports of the following laboratory findings and/or clinical diagnoses, generally of mild or moderate severity (CTCAE Grade 1 or 2) and generally not requiring treatment discontinuation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: January 10, 2020
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of signed written informed consent prior to any study specific procedures

2. Female and/or male patients aged 18 years and over

3. Body weight higher than 30 Kg

4. Newly diagnosed histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx

5. Provision of biological material (tumor tissue and blood), provision of signed informed consent for translational research

6. Patients selected for a primary surgical treatment

7. No prior anti-cancer treatment for head and neck cancer

8. Performance status ECOG 0-1

9. Adequate hematological status: neutrophils (ANC) =1.5x109/L; platelets =100x109/L; haemoglobin =10g/dL

10. Adequate renal function: serum creatinine level 1.5 mg/dl and Glomelular Filtration Rate50 ml/min by Cockroft/Gault formula

11. Adequate liver function: serum bilirubin =1.5 x upper normal limit (ULN), alkaline phosphatase, AST (SGOT), ALT (SGPT) 5xULN

12. No active rheumatoid arthritis, active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation.

13. Ability to swallow tablets.

14. Regular follow-up feasible

15. Baseline evaluations performed before registration: clinical and blood evaluations no more than 1 week (7 days) prior to registration, tumour assessment (CT or MRI scan of the head and neck, chest, abdomen and pelvis at the discretion of the investigator) no more than 30 days prior to registration

16. Treatment initiation planned less than 1 week (7 days) after registration

17. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

1. Women <50 years of age would be considered post-menopausal if theyhave been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

2. Women =50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). For female patients of childbearing potential, negative serum pregnancy test within 1 week (7 days) prior of starting study treatment

18. Women of childbearing potential and their partners, who are sexually active, must agree to the use of TWO highly effective forms of contraception in combination, throughout the period of taking study treatment and for at least 1-6 month (according to the treatment group) after last dose of study drug(s) (where applicable). Male patients and their partners, who are sexually active and of childbearing potential, must agree to the use of TWO highly effective forms of contraception in combination, throughout the period of taking study treatment and for 3- 6 months (according tot he treatment group) after last dose of study drug(s) (where applicable).

Exclusion Criteria:

1. Metastatic or locally advanced unresectable disease

2. Uncontrolled hypercalcemia

3. Concomitant unplanned antitumour therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy)

4. Treatment with any other investigational medicinal product within 28 days prior to study entry

5. Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab

6. Receipt of live attenuated vaccine within 30 days prior to the first dose of IMP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IMP and up to 30 days after the last dose of IMP.

7. Treatment with CYP3A4 inhibitors as well as inducers, unless discontinued 7 days prior to randomization

8. Any of the following within 3 months prior to inclusion: grade 3-4 gastrointestinal bleeding, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulitis

9. Other concomitant or previous malignancy, except: i) adequately treated in-situ carcinoma of the uterine cervix, ii) basal or squamous cell carcinoma of the skin, iii) cancer in complete remission for 5 years

10. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days

11. Pregnant or breastfeeding women

12. Patients with known allergy to any excipients to study drugs

13. History of myocardial infarction and/or stroke or other arterialthrombotic events or pulmonary embolism or unstable angina pectoris within 6 months prior to registration

14. No features suggestive of myelodysplastic syndrome/ acute myeloid leukemia MDS/ AML

15. Poorly controlled cardiac arrhythmias

16. Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, bowel obstruction or inability to take oral medication

17. Active rheumatoid arthritis, active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation.

18. History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan

19. Other clinically significant disease or co-morbidity which may adversely affect the safe delivery of treatment within this trial

20. Known history of positive tests for human immunodeficiency virus (HIV) infection, hepatitis A or C virus, acute or chronic active hepatitis B infection

21. History of severe tumour bleeding or bleeding disorders

22. No blood transfusion within the 28 days prior to study

23. Poorly controlled anti-coagulation therapy (INR3.0 on coumadin or heparin compounds)

24. Palliative radiation therapy within 4 weeks prior to registration

25. Pregnancy or men or women of reproductive age not agreeing to use contraceptive measures

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Squamous Cell Carcinoma of Head and Neck
• Squamous Cell Carcinoma of the Head and Neck

Intervention

Drug:
• Olaparib
50/25 mg BD split x 5 days
• Cisplatin
60 mg/m^2 d1-d5
• Olaparib
300 mg BD x 21-28 days.
• Durvalumab
1500 mg d1

Locations

Country	Name	City	State
Greece	University Hospital "Attikon", 2nd Department of Internal Medicine, Division of Oncology	Athens
Greece	Euromedica General Clinic of Thessaloniki	Thessaloníki	Thessaloniki

Sponsors (2)

Lead Sponsor	Collaborator
Hellenic Cooperative Oncology Group	AstraZeneca

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Investigation of the change in the tumour Ki-67 before and after treatment with the combination of olaparib + durvalumab or olaparib + cisplatin or olaparib monotherapy.		At baseline and at the day of the surgery or 2nd biopsy (at days 23-29 days)
Secondary	Objective response rate according to RECIST 1.1 criteria		Imaging studies will be performed at baseline and on week 4
Secondary	Pathologic complete response rate		On week 4 only for operable patients
Secondary	Metabolic response rate assessed by FDG-PET/CT scan (optional)		At baseline, on week 4
Secondary	Number of participants with tolerability to the treatment.		From the 1st day of therapy and every week for 4 weeks maximum and 90 days after last therapy administration
Secondary	Surgical complication rate		Up to 30 days after surgery or the day of initiation of the next anticancer therapy
Secondary	Mutations in genes associated with DNA repair		At baseline, on day of surgery or the 2nd biopsy (at days 23-29)
Secondary	Expression of tissue biomarker: PARP1		At baseline, on day of surgery or the 2nd biopsy (at days 23-29)
Secondary	Expression of tissue biomarker: BRACA1,2		At baseline, on day of surgery or the 2nd biopsy (at days 23-29)
Secondary	Expression of tissue biomarker: ERCC1		At baseline, on day of surgery or the 2nd biopsy (at days 23-29)
Secondary	Expression of tissue biomarker: PDL-1		At baseline, on day of surgery or the 2nd biopsy (at days 23-29)
Secondary	Expression of tissue biomarker: TILs		At baseline, on day of surgery or the 2nd biopsy (at days 23-29)
Secondary	Plasma methylation biomarker: PARP1 methylation in plasma cell-free DNA		At baseline, a day before surgery and 90 days after surgery
Secondary	Plasma methylation biomarker: BRCA1,2 methylation in plasma cell-free DNA		At baseline, a day before surgery and 90 days after surgery
Secondary	Plasma methylation biomarker: ERCC1 methylation in plasma cell-free DNA		At baseline, a day before surgery and 90 days after surgery
Secondary	Plasma methylation biomarker: RAD51C methylation in plasma cell-free DNA		At baseline, a day before surgery and 90 days after surgery
Secondary	Single-nucleotide polymorphisms: PARP-1 Val762Ala		Sample will be collected once at baseline
Secondary	Single-nucleotide polymorphisms: ERCC1 Asn118Asn (C/T)		Sample will be collected once at baseline
Secondary	Single-nucleotide polymorphisms:ERCC2 Lys751Gln (T/G)		Sample will be collected once at baseline
Secondary	Single-nucleotide polymorphisms: GSTP1 Ile105Val (A/G)		Sample will be collected once at baseline
Secondary	Single-nucleotide polymorphisms: XPD Lys751Gln (A/C, C/C)		Sample will be collected once at baseline
Secondary	Single-nucleotide polymorphisms: XRCC1 Arg399Gln (G/A)		Sample will be collected once at baseline
Secondary	Circulating tumor cells (CTCs) evaluated for DNA repair biomarkers		At baseline, a day before surgery and 90 days after surgery
Secondary	Circulating tumor cells (CTCs) evaluated for PD-L1		At baseline, a day before surgery and 90 days after surgery